Skip to main content

ADVERTISEMENT

diffuse large B-cell lymphoma

Research in Review
06/23/2017
JCP Editors
A new prognostic indicator involving monocytes has been identified for patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL), according to research presented at the 22nd Congress of the European...
A new prognostic indicator involving monocytes has been identified for patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL), according to research presented at the 22nd Congress of the European...
A new...
06/23/2017
Journal of Clinical Pathways
Research in Review
06/22/2017
JCP Editors
Patients with diffuse large B-cell lymphoma (DLBCL) benefit from improved survival outcomes when treated with a combination therapy rather than monotherapy, according to research presented at the 22nd Congress of the...
Patients with diffuse large B-cell lymphoma (DLBCL) benefit from improved survival outcomes when treated with a combination therapy rather than monotherapy, according to research presented at the 22nd Congress of the...
...
06/22/2017
Journal of Clinical Pathways
Research in Review
05/31/2017
JCP Editors
Noninvasive sampling of diffuse large B-cell lymphoma (DLBCL) circulating tumor DNA enables early detection of focal and broad somatic copy number alterations, according to research that will be presented at the 2017...
Noninvasive sampling of diffuse large B-cell lymphoma (DLBCL) circulating tumor DNA enables early detection of focal and broad somatic copy number alterations, according to research that will be presented at the 2017...
...
05/31/2017
Journal of Clinical Pathways
Research in Review
05/12/2017
JCP Editors
Lenalidomide maintenance therapy for 24 months after obtaining a complete or partial response to standard chemotherapy significantly prolongs progression-free survival (PFS) in older patients with diffuse large...
Lenalidomide maintenance therapy for 24 months after obtaining a complete or partial response to standard chemotherapy significantly prolongs progression-free survival (PFS) in older patients with diffuse large...
...
05/12/2017
Journal of Clinical Pathways
Research in Review
04/28/2017
JCP Editors
Lenalidomide maintenance therapy for 24 months after a complete or partial response to standard chemotherapy significantly prolongs progression-free survival (PFS) in older patients with diffuse large B-cell...
Lenalidomide maintenance therapy for 24 months after a complete or partial response to standard chemotherapy significantly prolongs progression-free survival (PFS) in older patients with diffuse large B-cell...
...
04/28/2017
Journal of Clinical Pathways
Research in Review
04/27/2017
JCP Editors
A recent meta-analysis identified a strong correlation between an inflammation marker and survival outcomes for patients with diffuse large B-cell lymphoma, published in PLOS One (published online April 25, 2017;...
A recent meta-analysis identified a strong correlation between an inflammation marker and survival outcomes for patients with diffuse large B-cell lymphoma, published in PLOS One (published online April 25, 2017;...
A...
04/27/2017
Journal of Clinical Pathways
Research in Review
04/12/2017
JCP Editors
Maintenance therapy with a targeting agent may provide survival benefits beyond first- and second-line chemotherapy in patients with diffuse large B-cell lymphoma, according to an analysis published in PLOS One...
Maintenance therapy with a targeting agent may provide survival benefits beyond first- and second-line chemotherapy in patients with diffuse large B-cell lymphoma, according to an analysis published in PLOS One...
...
04/12/2017
Journal of Clinical Pathways